Massimo Di Nicola - Concepedia

Author

Massimo Di Nicola

Fondazione IRCCS Istituto Nazionale dei Tumori ORCID

Also Known As

Di Nicola, M., M Di Nicola, M Nicola, M. Di Nicola, M. NICOLA, M. Nicola, Maria Di Nicola, Marovza Nicola, Massimo Di Nicola, Massimo Di Nicola

303

Publications

10.3K

Citations

H-Index

107

Concepts

All Affiliations

Fondazione IRCCS Istituto Nazionale dei Tumori University of Milan University of Turin Tumori Foundation Istituti di Ricovero e Cura a Carattere Scientifico

About

Massimo Di Nicola is an author at Fondazione IRCCS Istituto Nazionale dei Tumori specializing in medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	44	2.1K
2	Health Sciences	13	15	728
3	Engineering	1	1	23
4	Natural Sciences	1	1	43
5	Allergy	1	1	18

Massimo Di Nicola

109

Publications

9.6K

Citations

H-Index

Page 1

	Year	Citations
Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli Massimo Di Nicola, Carmelo Carlo‐Stella, Michele Magni, Blood	2002	3.2K
High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma Alessandro M. Gianni, Marco Bregni, Salvatore Siena, New England Journal of Medicine	1997	478
Inhibition of the ABL Kinase Activity Blocks the Proliferation of BCR/ABL+Leukemic Cells and Induces Apoptosis Carlo Gambacorti‐Passerini, Philipp le Coutre, Luca Mologni, Blood Cells Molecules and Diseases Hematological MalignancyCancer ResearchMixed-phenotype Acute LeukemiaInduces ApoptosisApoptosis	1997	317
A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus–associated lymphoid malignancies Susan P. Perrine, Olivier Hermine, Trudy N. Small, Blood	2006	292
Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Salvatore Siena, Massimo Di Nicola, Marco Bregni, PubMed	1995	231
Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion Michele Magni, Massimo Di Nicola, Liliana Devizzi, Blood	2000	217
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial Luis Paz‐Ares, Tae Min Kim, David Vicente, Journal of Thoracic Oncology Translational MedicineBintrafusp AlfaMedicineImmunologyClinical Trials	2020	213
An Expanded Peripheral T Cell Population to a Cytotoxic T Lymphocyte (Ctl)-Defined, Melanocyte-Specific Antigen in Metastatic Melanoma Patients Impacts on Generation of Peptide-Specific Ctls but Does Not Overcome Tumor Escape from Immune Surveillance in Metastatic Lesions Andrea Anichini, Alessandra Molla, Roberta Mortarini, The Journal of Experimental Medicine	1999	191
Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. Alessandro M. Gianni, Salvatore Siena, Marco Bregni, Journal of Clinical Oncology	1997	190
WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer Lorenzo Castagnoli, Valeria Cancila, Sandra Romero‐Córdoba, Oncogene	2019	179

Page 1